Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors

• US 7,763,613 B2
• Filed: 06/28/2005
• Issued: 07/27/2010
• Est. Priority Date: 06/30/2004
• Status: Expired due to Fees

• Current Assignee: Schering Corporation (Merck & Co., Inc.)
• Original Assignee: Schering Corporation (Merck & Co., Inc.)
• Inventors: Josien, Hubert B., Xu, Ruo, Bara, Thomas A.
• Primary Examiner(s): Anderson; Rebecca L
• Application Number:
  US11/168,797
• Publication Number:
  US 20060040936A1
• Time in Patent Office: 1,855 Days
• Field of Search: 514/233.2, 544/116
• US Class Current: 514/233.2
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 265/30 not condensed with other rings
• CPC Class Codes: C07D 413/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 451/02 containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
• CPC Class Codes: C07D 487/08 Bridged systems

Abstract

Disclosed are novel gamma secretase inhibitors of the formula:

Also disclosed are methods for inhibiting gamma secretase, for treating one or more neurodegenerative diseases, for inhibiting the deposition of beta amyloid protein, and for treating Alzheimer'"'"'s disease using the compounds of formula (I).

Claims

1. A compound, or a pharmaceutically acceptable salt thereof, having the following structure:

4. A pharmaceutical composition comprising the compound of claim 1 and at least one pharmaceutically acceptable carrier.

5. The compound of claim 1 in purified form.

2. A compound, or a pharmaceutically acceptable salt thereof, having the following structure:

6. A pharmaceutical composition comprising the compound of claim 2 and at least one pharmaceutically acceptable carrier.

8. The compound of claim 2 in purified form.

3. A compound, or a pharmaceutically acceptable salt thereof, having the following structure:

7. A pharmaceutical composition comprising the compound of claim 3 and at least one pharmaceutically acceptable carrier.

9. The compound of claim 3 in purified form.